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During induced myocardial ischemia for cardiac sur- 
gery, myocardial stunning occurs and aerobic metabo- 
lism of glucose, fatty acids, and lactate is inhibited as 
anaerobic pathways predominate. Even following re- 
perfusion, stunned myocardium uses oxygen and sub- 
strate inefficiently leading to poor functional recovery 
as less mechanical work is developed per oxygen uti- 
lized. Amino acids potentially can act as cardiac meta- 
bolic substrates during and after ischemia, utilizing the 
transamination of amino acids by the malate-aspartate 
shuttle to form high energy phosphates via the tricar- 
boxylic acid cycle. We investigated if “preloading” 
hearts with a physiologic spectrum of amino acids could 
increase postischemic myocardial recovery. Isolated 
perfused rabbit hearts were subjected to 120 min of 
34°C cardioplegic ischemia. Hearts received cardiople- 
gia alone as controls or were “preloaded” with a 0.05% 
amino acid perfusion for 30 min prior to cardioplegic 
ischemia. Following reperfusion, analysis of functional 
recovery revealed that contractility and cardiac effi- 
ciency were improved with amino acids substrate pre- 
loading. The mechanism of this may be due to uptake of 
amino acids prior to ischemia, which are later utilized 
for internal reparative work during ischemia and ex- 
ternal contractile work after ischemia. o 1992 Academic 
Press, Inc. 
INTRODUCTION 
During non-ischemic aerobic metabolism amino acids 
contribute insignificantly (less than 5%) to the genera- 
tion of energy for the heart, as the myocardium preferen- 
tially oxidizes carbohydrates (glucose) and lipids (fatty 
acids) to form ATP for the contraction (external work) 
’ Presented at the Annual Meeting of the Association for Academic 
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of Michigan Hospital, Section of Thoracic Surgery, 2120D Taubman 
Center, Box 0344, Ann Arbor, MI 48109. 
and repair of subcellular structures (internal work) [ 11. 
However, during ischemia, aerobic metabolism ceases 
and less efficient anaerobic pathways predominate. An- 
aerobic glycolysis of glucose cannot produce adequate 
high-energy phosphate compounds to maintain critical 
cellular function and the result is a breakdown of cellu- 
lar organelles and poor contractility following reperfu- 
sion. Theoretically however, amino acids, through trans- 
amination to tricarboxylic acid cycle intermediates and 
subsequent anaerobic substrate phosphorylation, could 
provide for energetics during ischemia and protect the 
ischemic myocardium from damage, thereby improving 
cardiac function after ischemia. Furthermore, if amino 
acids could be taken up and were present in adequate 
quantities at reperfusion, they could serve as a further 
substrate for energetics upon reflow, during early reper- 
fusion when normal aerobic mechanisms for utilization 
of glucose and fatty acids continue to be inhibited, de- 
spite the reintroduction of oxygen. This present study 
“preloaded” hearts with amino acids prior to ischemia at 
a time when the heart has the ability to uptake these 
compounds and examined functional recovery after an 
ischemic episode, analogous to that which occurs during 
clinical cardiac surgery. 
MATERIALS AND METHODS 
Preparation of isolated hearts. New Zealand White 
rabbits (male or female, 2-3 kg body weight) were anes- 
thetized with sodium pentobarbital(45 mg/kg) and hepa- 
rinized (700 units/kg). Heart were rapidly excised and 
immersed in ice-cold physiologic salt solution (PSS) 
containing 118.0 miV NaCl, 4.0 m&f KCI, 22.3 m&f 
NaHCO,, 11.1 mM glucose, 0.66 mM K,HPO,, 1.23 mA4 
MgCl,, and 2.38 mA4 CaCl,. The aorta was cannulated 
in the Langendorff mode and perfused with PSS which 
was equilibrated with 95% O,-5% CO, at 37°C and pH 
7.4. Perfusion pressure was maintained at 80 mm Hg. 
The perfusion solution was filtered and was not recircu- 
lated. An incision was made in the left atrium and a 
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fluid-filled latex balloon was passed through the mitral 
orifice and placed in the left ventricle. The balloon al- 
lowed for passive venting of the left ventricular (LV) 
cavity. A catheter-mounted micromanometer was posi- 
tioned in the LV (Model PC250, Millar, Houston, TX) 
and LV pressure was recorded continuously. The bal- 
loon was connected to a Statham P23 XL pressure trans- 
ducer for continuous measurement of left ventricular 
pressure (LVP) and output from the pressure transducer 
was electronically differentiated to enable continuous re- 
cording of the first derivative of LVP (dP/dt). End-dia- 
stolic volume was inferred from balloon volume. The su- 
perior vena cava and inferior vena cava were ligated. The 
pulmonary artery was cannulated to enable timed col- 
lection measurements of coronary flow and the cannula 
was connected to an oxygen meter (Chemical microsen- 
sor, Diamond Electra-Tech, Inc., Ann Arbor, MI) for 
continuous measurement of the partial pressure of oxy- 
gen in the coronary effluent. All hearts were maintained 
at 37°C by means of a circulating water jacket during the 
control baseline period. 
The analog signals were continuously recorded on a 
pressurized ink chart recorder (Model 26OOS, Gould, 
Inc., Cleveland, OH) and an online computer (AST Pre- 
mium/386, AST Research Inc., Irvine, CA). During the 
control period, a standardized volume of saline was intro- 
duced into the LV balloon producing an end diastolic 
pressure of 5.5 f 3.3 mm Hg. The same volume was used 
to evaluate and characterize isovolumic cardiac func- 
tion; developed pressure (DP) was defined as peak sys- 
tolic pressure minus end-diastolic pressure. The product 
of heart rate and DP (PRP, mm Hg/min) was calculated 
to provide an estimate of changes in myocardial work. 
Myocardial oxygen consumption (MVO,) was calculated 
as MVO, = CF X [ (PaO, - PvO,) X (c/760)], where CF is 
coronary flow (ml/min/g), (PaO, - PvO,) is the differ- 
ence in the partial pressure of oxygen (PO,, mm Hg) 
between perfusate and coronary effluent flow, c is the 
Bunsen solubility coefficient of 0, in perfusate at 37°C 
(22.7 ~10,. atm-’ * ml perfusate). The PO, of the perfus- 
ate was 663 mm Hg. Coronary flow was measured by 
performing timed collections of the pulmonary effluent 
flow with a graduated cylinder. Oxygen extraction (0, 
EXT) was calculated as 0, EXT = MVO,/oxygen con- 
tent in the perfusate. Wet weight of the heart was deter- 
mined at the conclusion of each experiment after trim- 
ming the great vessels and fat and blot drying with 
eight-layer cotton gauze. 
Preparation of amino acids. The solution utilized 
was a commercially approved and available 10% Trava- 
sol Injection which contains 15 amino acids, both essen- 
tial and nonessential; 730 mg leucine; 600 mg isoleucine; 
580 mg lysine (added as the hydrochloride salt); 580 mg 
valine; 560 mg phenylalanine; 480 mg histidine; 420 mg 
threonine; 400 mg methionine; 180 mg tryptophan; 2.07 
g alanine; 1.15 g arginine; 1.03 g glycine; 680 mg proline; 
500 mg serine; 40 mg tyrosine; in each 100 ml (Baxter 
Healthcare Corp., Deerfield, IL). On the day of each ex- 
periment, the amino acid solution with 2.0 tipyruvate 
was made in 0.05% concentration in PSS. 
Experimental protocol. Baseline data were obtained 
after an equilibration period of approximately 30 min. 
There were 10 hearts in both the control and amino 
acid-treated groups. Following collection of baseline 
data, 60 ml of modified St. Thomas cardioplegia solution 
was injected into the aorta at 1 ml/set at the beginning 
of the 2-hr ischemic period, which was induced by in- 
terrupting aortic retrograde flow into the coronaries. All 
hearts were maintained at 34°C by means of a circulat- 
ing water jacket during the cardioplegic ischemia period. 
Fifteen milliliters of cardioplegia solution was injected 
every 30 min thereafter. At the end of the 2-hr ischemic 
period, the hearts were reperfused with standard oxy- 
genated PSS solution. Reperfusion was performed with 
perfusate temperature at 37°C and delivered with pres- 
sure at 80 mm Hg. Defibrillation was performed as 
needed. During the initial 15 min of reperfusion, the in- 
traventricular balloon was kept deflated to allow for re- 
covery. After the initial 15 min of reperfusion, the LV 
balloon was refilled to the preischemic control volume 
and isovolumic measurements of cardiac function were 
obtained. The LV balloon remained inflated for the re- 
mainder of reperfusion. Hemodynamic data were re- 
corded every 15 for 45 min to compare with baseline data 
in order to determine the degree of functional recovery 
in each heart. The experimental design for this model is 
well established and has been published previously [2, 
31. All animals received humane care in compliance with 
the Principles of Laboratory Animal Care formulated by 
the National Society for Medical Research. 
Statistical analysis. Values reported are means + 
standard deviation. Data were evaluated with repeated 
measures ANOVA within groups and single factor analy- 
sis of variance across groups. When significant F values 
were obtained, Scheffe’s test was used to distinguish 
when time periods or groups differed from one another 
significantly. 
RESULTS 
There were no significant differences among the two 
groups in terms of heart wet weight (6.02 + 1.21 g in 
control group and 6.18 * 0.98 g in amino acid group, 
respectively), postischemic myocardial water content 
(86.2 + 1.9% in control group and 86.1 * 1.2% in amino 
acid group), or end diastolic volume (0.97 + 0.16 ml in 
control group and 0.97 +- 0.36 ml in amino acid group). 
During baseline recording, developed pressure was lOO- 
140 mm Hg for all of the hearts. There were no signifi- 
cant hemodynamic differences among the groups during 
baseline conditions with the exception of positive and 
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TABLE 1 
Hemodynamics (Means f SD) 
Baseline REP 15 Min REP 30 Min REP 45 Min 
PSP (mm Hg) 
CONT 119.6 + 8.4 84.1 + 11.9** 84.7 + 8.5** 80.8 f 10.8** 
AM 119.5 f 10.4 90.4 * 11.4** 91.4 f 12.2** 92.2 f 12.7**** 
EDP (mm Hg) 
CONT 6.7 + 3.1 48.4 k 16.4** 35.5 + 14.7** 30.0 + 13.3** 
AM 4.4 + 3.6 32.4 k 17.7*,** 23.7 + 15.4** 20.5 + 13.8 
DP (mm Hg) 
CONT 112.9 f 9.2 35.7 f a.4** 49.2 f 11.0** 50.8 + 10.8** 
AM 115.1 f 11.6 58.0 + 26.1*,** 67.7 + 23.8*,** 71.7 + 23.4**** 
dP/dt, (mm Hg/sec) 
CONT 1812 + 268 560 k 151** 788 + 1a2** 853 k 224** 
AM 1608 & 152* 772 -t 301** 1009 _t 301** 1035 + 309** 
-dP/dt,, (mm Hg/sec) 
CONT 1306 + 145 422 k 104** 564 + ill** 589 k llO** 
AM 1102 f 194* 534 k 252** 632 + 219** 676 f 217** 
HR (beats/min) 
CONT 185.6 f 26.9 168.6 f 26.9 176.5 + 29.3 176.0 & 31.4 
AM 195.7 f 21.5 175.1 f 14.3 181.8 + 18.1 183.8 + 19.6 
PRP (lo3 mm Hg/min) 
CONT 21.00 + 3.85 5.98 + 1.55** 8.66 + 2.27** 8.84 + 1.98** 
AM 22.65 + 4.16 10.22 f 4.60*,** 12.41 + 4.55**** 13.30 + 4.61**** 
CF (ml/min/g tissue) 
CONT 9.11 f 2.55 6.57 k 1.25** 6.16 + 1.53** 5.83 * 1.12** 
AM 8.08 + 1.09 6.78 k 0.86** 6.56 f 1.03** 6.73 f 0.92** 
MVO, (pl/min/g tissue) 
CONT 106.6 k 29.8 60.4 k 20.3** 65.0 + 17.5** 67.8 + 13.3** 
AM 111.9 rt_ 16.5 60.3 -t 21.6** 69.3 + 26.9** 74.1 k 28.0** 
0, EXP (%) 
CONT 59.9 + 11.4 46.7 f 15.6 54.0 + 12.5 58.9 k 7.8 
AM 70.1 + 9.4 44.8 + 15.6** 52.6 k 18.0 55.2 + 19.7 
Note. Hemodynamic indexes as determined in isolated reperfused hearts at 15,30, and 45 min of reperfusion as described under Materials and 
Methods. Ten hearts were used per group. PSP, peak systolic pressure; EDP, end diastolic pressure; DP, developed pressure; dP/dt-, maxi- 
mum first derivative of left ventricular pressure; HR, heart rate; PRP, product of HR and DP; CF, coronary flow; MVO,, myocardial oxygen 
consumption; 0, EXT, oxygen extraction; CONT, control group; AM, amino acid-treated group. 
* P < 0.05 compared to controls. 
** P < 0.05 compared to baseline. 
negative dP/dt,, values. There was no hemodynamic 
deterioration or change during the 30 min of preinfusion 
of amino acid. 
Hemodynamic results are summarized in Tables 1 and 
2. The amino acid hearts were characterized by higher 
postischemic developed pressures as summarized in Fig. 
1. Average results of percentage recovery of peak posi- 
tive dP/dt are summarized in Fig. 2. After 15,30, and 45 
min of reperfusion, developed pressure recovered to 32 f 
8,44 f 11, and 45 f 11% of baseline, respectively, in the 
control group. In the amino acid group, recovery was 
significantly better averaging 50 f 20,58 +- 17, and 62 + 
17% of baseline, respectively. The dP/dt, recovered to 
31 f 9, 44 +- 11, and 48 + 14% of the baseline value, 
respectively, in controls. The counterpart values in the 
amino acid group were significantly higher, averaging 48 
f 17, 63 f 18, and 64 + 17% of baseline, respectively. 
End-diastolic pressure was significantly lower in the 
amino acid group compared to the control group after 
reperfusion (Table 1). The recovery of end diastolic LV 
pressure is also summarized in Fig. 3. The pressure-rate 
products were significantly higher in the amino acid 
group than those in control group at all time during re- 
perfusion (Table 1). The recovery of coronary flow was 
significantly higher in the amino acid group only at 45 
min of reperfusion compared to the control group (84 + 
14% of baseline in the amino acid group vs 66 f 14% of 
baseline in controls, Fig. 4). 0, EXT was higher in con- 
trol group at 45 min reperfusion time point, perhaps in- 
duced by the lower CF. Myocardial oxygen consumption 
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TABLE 2 
Postischemic Recovery (Percentage of Baseline, 
Means + SD) 
REP REP 



























31.8 + 8.2 
49.7 2 20.0* 
31.4 f 9.2 
41.5 * 17.7* 
32.4 + 7.7 
48.8 k 23.2* 
90.8 + 5.1 
90.2 + 9.7 
28.9 f 7.3 
43.9 t 16.9* 
74.9 + 14.5 
85.0 f 14.2 
58.3 + 20.3 
53.0 + 15.9 
81.6 f 33.9 
62.9 f 17.2 
43.8 + 10.7 
58.2 k 17.6* 
44.2 31 11.6 
62.7 f 18.9* 
43.4 r 8.3 
57.9 + 19.9* 
95.2 + 8.4 
93.4 + 9.3 
41.7 t 10.5 
53.7 + 15.4 
70.5 + 18.1 
81.9 r 13.0 
63.7 r 19.9 
60.8 + 19.4 
94.3 + 32.7 
73.6 + 18.8 
45.3 + 11.1 
61.8 + 17.2* 
48.0 k 14.6 
63.8 + 17.1* 
45.4 zk 8.9 
61.8 Ii 19.7* 
94.8 k 9.5 
94.4 k 9.6 
42.7 k 9.8 
57.7 k 15.6* 
66.8 * 14.4 
84.5 It 14.9* 
66.3 + 14.2 
65.6 k 20.7 
102.2 + 26.5 
71.4 ? 21.6* 
Note. The hemodynamic indexes were determined in isolated reper- 
fused hearts at 15, 30, and 45 min of reperfusion as described under 
Materials and Methods. Ten hearts were used in each group. DP, de- 
veloped pressure; dP/dt,, maximum derivative of left ventricular 
pressure; HR, heart rate; PRP, product of HR and DP; CF, coronary 
flow; MVO,, myocardial oxygen consumption; 0, EXT, oxygen ex- 
traction; CONT, control group; AM, amino acid-treated group. 
* P < 0.05 compared to control group. 
was not significantly different between the two groups 
during reperfusion. 
DISCUSSION 
The beneficial effect of amino acid preloading upon 
diastolic recovery and the higher recovery of DP and 
dP/dt, indicate that amino acid preloading, possibly 
by metabolic intervention, improved ischemic tolerance 
and/or minimized the effects of reperfusion in this 
model. This beneficial effect of amino acid preloading 
was not felt to be due to changes in coronary vasodila- 
tion, as coronary flow during the 30-min preloading pe- 
riod was similar in both groups (controls, 9.11 + 2.55 vs 
amino acid preload, 8.08 + 1.09, ml/min/g tissue), nor 
was this a primary effect upon alteration in myocardial 
B l p<.05 
25 
15 MIN 30 MIN 45 MIN 
REPERFUSION 
FIG. 1. Average data (means + SE) on the left ventricular pres- 
sure during baseline 15, 30, and 45 min after reperfusion. Developed 
pressure was significantly higher than control (CONT) with amino 
acid preloading (AM). 
oxygen consumption which remained unchanged be- 
tween groups during the entire time course. 
The metabolic pathways for anaerobic energy produc- 
tion via amino acid substrate level phosphorylation dur- 
ing ischemia include transamination of glutamate with 
pyruvate to alanine and a-ketoglutarate with subse- 
quent conversion to succinate and transamination of as- 
partate to oxaloacetate, which is converted subsequently 
to malate, fumarate, and then to succinate. Other amino 
acids can be utilized by alternate incorporation in the 
tricarboxcylic acid cycle including glycine, lysine, and 
methionine. Still others may provide for energetics by 
interconversion (arginine, phenylalanine, leucine, iso- 
leucine, valine, and tyrosine) before inclusion into a met- 
abolic pathway. These pathways ultimately lead to 
formation of high-energy compounds in the mitochon- 
dria [4]. 
- 801 I 




FIG. 2. Average data (means + SE) on the percentage recovery of 
peak positive dP/dt at 15, 30, and 45 min after reperfusion. Data are 
presented as percentages of baseline values. Similar to the findings 
with developed pressure, amino acid preloading (AM) resulted in a 
significant improvement of this parameter of systolic cardiac perfor- 
mance compared with control (CONT). 
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BASE LINE 15 MIN REP 30 MIN REP 45 MIN REP 
FIG. 3. Average data (means 2 SE) on the percentage recovery of 
left ventricular end diastolic pressure at 15,30, and 45 min after reper- 
fusion. Data are presented as mm Hg. Amino acid preloading (AM) 
resulted in a significant improvement of this parameter of diastolic 
cardiac performance compared with control (CONT). 
The transaminase reactions which catalyze the con- 
version of pyruvate to alanine and cY-ketoglutarate to 
glutamate are major metabolic branch points joining 
amino acid and carbohydrate metabolism. Pyruvate, as 
provided in this study is the probable source of the three 
carbon fragment from which alanine is produced in car- 
diac muscle and glutamate is the source of the amino 
nitrogen for the transanimation reaction. During anaer- 
obic metabolism, citrate is formed from glutamate via 
2-oxoglutarate and isocitrate, utilizing pyruvate as an 
amino acceptor. Because citrate inhibits the glycolytic 
enzyme phosphofructokinase which is the regulatory 
enzyme for turning “on” aerobic myocardial glucose uti- 
lization, anaerobic metabolism with its obligate produc- 
tion of citrate inhibits aerobic glucose utilization even 
after the reintroduction of oxygen. The quantity of myo- 
cardial citrate release during postischemic recovery has 
been positively correlated with a return of aerobic func- 
tion. These findings suggest that myocardial ischemia 
may have a profound effect on myocardial metabolism 
which lasts many times longer than the ischemic inter- 
val itself. Indeed many but not all myocardial metabolic 
studies have demonstrated that the stunned postisch- 
emit heart is inefficient in its utilization of delivered 
oxygen [5]. This oxygen utilization inefficiency disables 
the heart from repleting high energy phosphates or meet- 
ing the internal reparative work required for the myo- 
cardium and the end result is poor postischemic perfor- 
mance [6]. 
Clinical studies have documented that myocardial me- 
tabolism is abnormal during the first hours of reperfu- 
sion after a period of myocardial ischemia. Despite the 
reintroduction of oxygen, there is little or no uptake of 
carbohydrate or lipid substrates up to 4 hr after coronary 
artery bypass operations and consequently resumption 
of aerobic metabolism is suppressed [7]. Although ele- 
vated serum levels of glucose, lactate, pyruvate, and p- 
OH-butyrate were noted, no uptake of these substrates 
was observed. Interestingly however, amino acids were 
the only exogenous substrates taken up by the heart. 
The pattern of uptake of amino acids suggested an adap- 
tation of postischemic myocardial metabolism, as al- 
most all amino acids were extracted from serum with 
glutamate and branch chain amino acids-leucine iso- 
leucine and valine being the quantitatively most impor- 
tant. These findings suggest that amino acids may serve 
a very important function in immediate postischemic 
metabolism. 
Confirming this adaptive change despite a “return” to 
the aerobic state, in a second study [8] the metabolism of 
cardiac and skeletal muscle following cardiac surgery 
was examined. While there was a net loss of amino acids 
from peripheral skeletal muscle, indicating continued 
aerobic metabolism, there was positive uptake of amino 
acids in the postischemic myocardium. The amino acids 
most significantly taken up in the myocardium were glu- 
tamate, aspartate, leucine, isoleucine, and tyrosine. The 
uptake of amino acids by human ischemic myocardium 
has been documented in patients who are made tran- 
siently ischemic by atria1 pacing [9]. In these patients 
with known coronary artery disease, rapid atria1 pacing 
resulted in increased myocardial glutamate extraction 
and alanine and glutamine turnover, indicating that glu- 
tamate extraction is closely connected with the energy 
supply status of the ischemic myocardium. These alter- 
ations of myocardial amino acid metabolism during and 
following ischemia had been confirmed in other studies 
[lo, 111, which demonstrated that patients with coro- 
nary artery disease subjected to ischemic stress all dem- 
onstrated increase myocardial uptake of glutamate and 
release of citrate indicating actual utilization of amino 
acids through the tricarboxylic acid cycle. 
90 
T T 
0 l p<o.os 1 
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REPERFUSION 
FIG. 4. Average data (means + SE) on the percentage recovery of 
coronary flow (CF) at 15, 30, and 45 min after reperfirsion. Data are 
presented as percentages of baseline values. Amino acid treatment 
(AM) resulted in significantly higher CF compared with control 
(CONT) at 45 min of reperfusion. 
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Many studies [12, 131, have demonstrated an in- 
creased tolerance to ischemia of the immature heart. 
The neonatal heart has been shown to contain a higher 
level of myocardial glutamate than adult hearts. It has 
been postulated that the altered amino acid metabolism 
noted during and following ischemia in conjunction with 
the higher endogenous supply of amino acids in the im- 
mature heart may be responsible for this increased neo- 
natal ischemic tolerance noted. Neonatal hearts [ 121, 
subject to metabolic blockade of amino acid transanima- 
tion with aminooxyacetic acid (AOA), which inhibits 
glutamate and aspartate utilization during ischemia, 
had severely impaired recovery of function as opposed to 
a control group not treated with AOA. This observation 
has lead to the use of glutamate [ 141 to enrich energy-de- 
pleted adult hearts during ischemia. Glutamate im- 
proved recovery of postischemic oxygen consumption 
and ventricular performance. 
To examine the potential mechanisms of this benefi- 
cial effect of amino acids on myocardial energy metabo- 
lism and return of cardiac function many studies have 
been undertaken. In isolated working rat hearts made 
ischemic for 60 min and reperfused for 30 minutes, isch- 
emia reduced ATP and all high energy phosphate com- 
pounds 50% or greater. In control hearts, postischemic 
function recovered only to 60%. However, in hearts per- 
fused with glutamate, cardiac function returned to 90% 
of baseline, but in this study high-energy phosphate re- 
covery was no better than in the controls. However, 
there was increased production of succinate indicating 
utilization of the TCA cycle and altered amino acid me- 
tabolism in the glutamate-treated hearts [15]. In con- 
trast to that study [16], others have shown the addition 
of glutamate to a cardioplegic solution not only in- 
creased postischemic recovery of function but also was 
associated with a lesser decline in the content of high- 
energy phosphate compounds during ischemia and lead 
to significantly better restoration of high-energy phos- 
phate content and ATP during reperfusion. This posi- 
tive effect of amino acid addition upon myocardial me- 
tabolism, postischemic function, and high-energy phos- 
phate content has been confirmed by others [17] 
utilizing glutamate, fumarate, malate, and oxaloacetate 
to perfuse isolated rat hearts. 
This protective effect of amino acids has been con- 
firmed in other models including the isolated rabbit 
heart where the effect of glutamate on isolated perfused 
newborn and adult rabbit hearts was shown to result in 
increased ATP production during reperfusion and im- 
provement of contractile function in both neonate and 
adult rabbit hearts [ 181. Furthermore, with glutamate 
administration an association between increasedproduc- 
tion of a-ketoglutarate and succinate denoting utili- 
zation of the TCA cycle for myocardial energetics and 
postischemic cardiac contractile performance was 
shown [19]. 
The effect of amino acids on enhancing mechanical 
recovery of ischemic myocardium was reconfirmed in 
perfused interventricular rabbit septa, which demon- 
strated that arginine, glutamate, ornithine, and aspar- 
tate significantly maintained developed tension during 
ischemia and enhanced postischemic recovery twofold 
over that noted in control septa not receiving amino 
acids. AOA again inhibited this protective effect sup- 
porting the hypothesis that amino acids act through an- 
aerobic intermediary transamination metabolic reac- 
tions [4]. In hypoxic ventricular papillary muscle strips 
the conversion of aspartate and glutamate to succinate 
for eventual metabolic use was stimulated 20-fold by 
glutamate, as shown by radiolabeled glutamate oxida- 
tion [20], confirmed by increased production of succi- 
nate in response to cardiac hypoxia [21] and cle nouo 
synthesis of alanine [22]. Finally, in isolated ischemic 
rat myocytes [l], the same amino acids as used in the 
present study significantly increased oxygen consump- 
tion indicating myocardial substrate metabolism is in- 
fluenced by available amino acids. 
As amino acid oxidation accounts for only about 5% of 
oxygen utilization and metabolism that occurs in the 
normal aerobic heart, the contribution of amino acids to 
myocardial energetics has been neglected. However, 
during ischemia and the critical period of early reperfu- 
sion when aerobic mechanisms are still inhibited, avail- 
able amino acid stores are critical in the repair of subcel- 
lular structures (internal work) and in the production of 
ATP for contraction (external work). While this is only 
a preliminary study, in this model, amino acid preload- 
ing improved postischemic function, perhaps by provid- 
ing substrate during these periods and enhancing high- 
energy compound production. This approach may be of a 
clinical benefit and warrants further study to identify 
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